My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.92 +1.22 (+2.86%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗

October 07, 2025

Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗

October 04, 2025

Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector.

Via Chartmill

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Both should have significant catalysts by the end of the decade.

Via The Motley Fool

17 Analysts Have This To Say About Exelixis ↗

September 17, 2025

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

September 15, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals ↗

September 15, 2025

EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector.

Via Chartmill

Is the Market Bullish or Bearish on Exelixis? ↗

August 26, 2025

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

July 22, 2025

Via Benzinga

Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy ↗

September 13, 2025

Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗

August 25, 2025

Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock ↗

August 22, 2025

EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup ↗

August 16, 2025

Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity.

Via Chartmill

The Analyst Verdict: Exelixis In The Eyes Of 19 Experts ↗

August 12, 2025

Via Benzinga

Exelixis EXEL Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗

August 03, 2025

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals ↗

July 30, 2025

EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount.

Via Chartmill

Assessing Exelixis: Insights From 20 Financial Analysts ↗

July 29, 2025

Via Benzinga

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans ↗

July 29, 2025

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.

Via Benzinga

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Exelixis Q2 Revenue Falls 11 Percent ↗

July 28, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 28, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 28, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech ↗

July 28, 2025

EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.

Via Chartmill

Topics Bankruptcy

Earnings Scheduled For July 28, 2025 ↗

July 28, 2025

Via Benzinga

Uncovering Potential: Exelixis's Earnings Preview ↗

July 25, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential ↗

July 25, 2025

EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗

July 22, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders.

Via Chartmill

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner ↗

July 20, 2025

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks ↗

July 19, 2025

EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.